IMBiologics (A493280) Stock Overview

A biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. More details

A493280 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the KR market

A493280 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

IMBiologics Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for IMBiologics
Historical stock prices
Current Share Price	₩24,050.00
52 Week High	₩104,000.00
52 Week Low	₩23,500.00
Beta	0
1 Month Change	-36.63%
3 Month Change	-68.40%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-76.88%

Recent updates

Shareholder Returns

	A493280	KR Biotechs	KR Market
7D	-14.0%	0.2%	10.0%
1Y	n/a	9.1%	179.9%

Return vs Industry: Insufficient data to determine how A493280 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A493280 performed against the KR Market.

Price Volatility

Is A493280's price volatile compared to industry and market?
A493280 volatility
A493280 Average Weekly Movement	17.2%
Biotechs Industry Average Movement	10.9%
Market Average Movement	8.8%
10% most volatile stocks in KR Market	16.2%
10% least volatile stocks in KR Market	4.5%

Stable Share Price: A493280's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A493280's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	n/a	Gyongsik Ha	imbiologics.com

IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen; IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells.

IMBiologics Corp. Fundamentals Summary

How do IMBiologics's earnings and revenue compare to its market cap?
A493280 fundamental statistics
Market cap	₩356.04b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A493280 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A493280 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A493280 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/21 12:27
End of Day Share Price	2026/06/19 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IMBiologics Corp. is covered by 0 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

IMBiologics Corp.KOSDAQ:A493280 Stock Report